Of 262 patients initially diagnosed with CIDP, 24 had nodal/paranodal antibodies. Median onset age was 59 years, predominantly male. Common features included asymmetric weakness (75%), distal involvement (54%), ataxia (66.7%), and tremor (16.7%). Dysautonomia, bulbar, and respiratory symptoms were present in 12.5% each; 8.3% had facial involvement. One-third of patients were initially misdiagnosed. Mean time to diagnosis was 30 months.

IVIG was used as first-line in 79% of patients, but 89.5% were refractory. Ten patients received Rituximab, with 70% showing significant improvement. MRC scores increased by a mean of 12 points (42→54), and INCAT decreased by 3.2 points (6→2.8), both exceeding thresholds for clinically meaningful change.

Autoimmune nodopathies differ from CIDP, with higher rates of ataxia and tremor, limited IVIG response, and notable improvement in strength and disability among patients treated with Rituximab. Early antibody testing may help identify these patients and reduce diagnostic and treatment delays. These findings highlight the importance of tailored management and suggest a role for B-cell–directed therapies in this subgroup.